argenx SE
| NASDAQ: ARGX | Healthcare / Biotechnology / Netherlands |
| 474.01 | +1.24 | +0.26% | Vol 164.50K | 1Y Perf 27.97% |
| Oct 4th, 2023 14:41 DELAYED |
| BID | 473.98 | ASK | 474.79 | ||
| Open | 482.63 | Previous Close | 472.77 | ||
| Pre-Market | 483.13 | After-Market | - | ||
| 10.36 2.19% | - - |
| Target Price | 450.71 | Analyst Rating | Strong Buy 1.43 | |
| Potential % | -5.00 | Finscreener Ranking | ★★★+ 51.81 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 52.71 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 49.30 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 64.74 | Earnings Rating | Strong Buy | |
| Market Cap | 26.26B | Earnings Date | 26th Oct 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.12 | |
| Beta | 0.74 |
Today's Price Range 473.71485.90 | 52W Range 333.07550.76 | 5 Year PE Ratio Range -41.90-27.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.05% | ||
| 1 Month | -8.16% | ||
| 3 Months | 23.90% | ||
| 6 Months | 28.66% | ||
| 1 Year | 27.97% | ||
| 3 Years | 80.24% | ||
| 5 Years | 551.92% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -21.93 | |||
ROE last 12 Months | -32.53 | |||
ROA (5Y Avg) | -9.31 | |||
ROA last 12 Months | -29.81 | |||
ROC (5Y Avg) | -25.65 | |||
ROC last 12 Months | -30.80 | |||
Return on invested Capital Q | -7.13 | |||
Return on invested Capital Y | -9.38 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 14.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -22.00 | ||||
| 7.00 | ||||
| 87.21 | ||||
| 57.40 | ||||
| -42.00 | ||||
| -16.41 | ||||
| 7.36 | ||||
| 53.69 | ||||
| 18.26B | ||||
| Forward PE | -162.25 | |||
| PEG | -0.82 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.20 | ||||
| 11.10 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -334.70 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 93.70 | ||||
| -340.30 | ||||
| -340.30 | ||||
| -481.80 | ||||
| -82.10 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 236.59M | ||||
| 4.28 | ||||
| 65.76 | ||||
| 61.03 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -1.69 | -1.69 | 0.00 |
| Q01 2023 | -2.34 | -0.52 | 77.78 |
| Q04 2022 | -3.08 | -0.70 | 77.27 |
| Q03 2022 | -3.50 | -4.26 | -21.71 |
| Q02 2022 | -4.76 | -3.81 | 19.96 |
| Q01 2022 | -5.07 | -4.36 | 14.00 |
| Q04 2021 | -4.88 | -4.76 | 2.46 |
| Q03 2021 | -4.48 | -4.40 | 1.79 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -1.48 | 19.13 | Positive |
| 12/2023 QR | -1.23 | 31.28 | Positive |
| 12/2023 FY | -5.10 | 18.40 | Positive |
| 12/2024 FY | -3.03 | 25.92 | Positive |
| Next Report Date | 26th Oct 2023 |
| Estimated EPS Next Report | -1.48 |
| Estimates Count | 14 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 164.50K |
| Shares Outstanding | 55.40K |
| Shares Float | 53.87M |
| Trades Count | 6.32K |
| Dollar Volume | 78.60M |
| Avg. Volume | 260.73K |
| Avg. Weekly Volume | 250.06K |
| Avg. Monthly Volume | 228.82K |
| Avg. Quarterly Volume | 303.30K |
argenx SE (NASDAQ: ARGX) stock closed at 472.77 per share at the end of the most recent trading day (a -2.99% change compared to the prior day closing price) with a volume of 251.37K shares and market capitalization of 26.26B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 188 people. argenx SE CEO is Tim Van Hauwermeiren.
The one-year performance of argenx SE stock is 27.97%, while year-to-date (YTD) performance is 24.8%. ARGX stock has a five-year performance of 551.92%. Its 52-week range is between 333.07 and 550.76, which gives ARGX stock a 52-week price range ratio of 64.74%
argenx SE currently has a PE ratio of -22.00, a price-to-book (PB) ratio of 7.00, a price-to-sale (PS) ratio of 87.21, a price to cashflow ratio of 57.40, a PEG ratio of -0.82, a ROA of -29.81%, a ROC of -30.80% and a ROE of -32.53%. The company’s profit margin is -82.10%, its EBITDA margin is -340.30%, and its revenue ttm is $236.59 Million , which makes it $4.28 revenue per share.
Of the last four earnings reports from argenx SE, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.48 for the next earnings report. argenx SE’s next earnings report date is 26th Oct 2023.
The consensus rating of Wall Street analysts for argenx SE is Strong Buy (1.43), with a target price of $450.71, which is -5.00% compared to the current price. The earnings rating for argenx SE stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
argenx SE has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
argenx SE has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.80, ATR14 : 12.72, CCI20 : -149.92, Chaikin Money Flow : 0.11, MACD : -5.72, Money Flow Index : 39.68, ROC : -10.46, RSI : 35.46, STOCH (14,3) : 9.09, STOCH RSI : 0.07, UO : 44.46, Williams %R : -90.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of argenx SE in the last 12-months were:
argenx SE
argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.
CEO: Tim Van Hauwermeiren
Telephone: +31 763030488
Address: Willemstraat 5, Breda 4811 AH, , NL
Number of employees: 188
TipRanks News for ARGX
Wed, 27 Sep 2023 01:20 GMT Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Pliant Therapeutics (PLRX)
- TipRanks. All rights reserved.Mon, 18 Sep 2023 10:32 GMT Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Innate Pharma (IPHA)
- TipRanks. All rights reserved.Mon, 24 Jul 2023 12:55 GMT Argenx Se (ARGX) Receives a Buy from Piper Sandler
- TipRanks. All rights reserved.Tue, 18 Jul 2023 09:10 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Argenx Se (ARGX) and Alector (ALEC)
- TipRanks. All rights reserved.Mon, 17 Jul 2023 10:30 GMT Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Pfizer (PFE)
- TipRanks. All rights reserved.Tue, 04 Jul 2023 17:25 GMT Argenx Se (ARGX) Receives a Buy from SVB Securities
- TipRanks. All rights reserved.
